Breathe Well Live Well
|
FDA Committee: Is Novel Anti-IL-5 Safe in Asthma?
MedPage Today In those two studies, with patients receiving reslizumab or placebo in addition to standard-of-care treatment, the asthma exacerbation frequency was decreased by at least half, with rate ratios of 0.50 (95% CI 0.37-0.67) and 0.41 (95% CI 0.28-0.59, P<0 … |
View full post on asthma – Google News
Scicasts (press release) (registration) (blog) |
Anti-IL-5 Cuts Exacerbations in Eosinophil Asthma
MedPage Today In one of the studies, the clinical asthma exacerbation (CAE) rate was halved (rate ratio 0.50, 95% CI 0.37-0.67, P<0.0001) among patients receiving reslizumab compared with those given placebo, reported Mario Castro, MD, MPH, of Washington University … Investigational drug can reduce asthma flareups Investigational biologics among emerging therapies for severe asthma Investigational Drug Could Reduce Asthma Flareups |
View full post on asthma – Google News